Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study of EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation

NCT01257594 is registered in ClinicalTrials.gov with Andrew B Lassman, MD as lead sponsor.

NCT NCT01257594
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01257594 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study of EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation
Lead sponsor
Andrew B Lassman, MD
Phase
Phase 1
Overall status
Completed
Start date
January 7, 2011
Completion date
December 31, 2018
Enrollment
22 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

brain cancer